OncoMatch/Clinical Trials/NCT03533816
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Is NCT03533816 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including EAGD T-cell infusion (Phase I) and EAGD T-cell infusion (Expansion) for acute myeloid leukemia.
Treatment: EAGD T-cell infusion (Phase I) · EAGD T-cell infusion (Expansion) — Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partially mismatched bone marrow transplant (haploidentical).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Demographics
Lab requirements
Kidney function
serum creatinine <2 mg/dl AND estimated (Cockcroft-Gault formula) or measured creatinine clearance (CrCl) ≥70 mL/min/1.73 m2
Liver function
serum bilirubin 1.5 upper limit of normal (ULN), AST/ALT 2.5 ULN, and alkaline phosphatase 2.5 ULN
Cardiac function
Normal left ventricular ejection fraction (LVEF) (50% or above) as measured by MUGA or Echocardiogram
Organ Function Criteria: Cardiac: Normal left ventricular ejection fraction (LVEF) (50% or above) as measured by MUGA or Echocardiogram. Pulmonary: FVC, FEV1 and DLCO (corrected) should be 50% or above of expected. Renal: serum creatinine level to be <2 mg/dl AND estimated (Cockcroft-Gault formula) or measured (takes priority if done) creatinine clearance (CrCl) must be equal or greater than 70 mL/min/1.73 m2. Hepatic: serum bilirubin 1.5 upper limit of normal (ULN), Aspartate transaminase (AST)/alanine transaminase (ALT) 2.5 ULN, and alkaline phosphatase 2.5 ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Kansas Cancer Center · Westwood, Kansas
- Ohio State University Medical Center · Columbus, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03533816 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify